Abbott's Trading Volume Surges 47.95% to $824 Million, Ranked 163rd in Daily Volume

On April 3, 2025, Abbott's trading volume reached $824 million, marking a 47.95% increase from the previous day. This surge placed Abbott at the 163rd position in terms of trading volume for the day. However, the stock price of Abbott (ABT) decreased by 0.23%.

Abbott's diversified business portfolio is strategically positioned to drive continued momentum in 2024. The company is making significant progress in its Established Pharmaceuticals Division (EPD) business, particularly in the advancement of biosimilars. Leveraging its strong presence in emerging markets, Abbott is scaling a capital-efficient licensing model to provide access to life-changing medicines. The first round of commercialization is scheduled for 2025, with biosimilars representing the highest growth segment in the branded generic pharmaceutical market.

Abbott continues to expand its Diagnostics business, which accounted for 23% of total revenues in the fourth quarter of 2024. The company has seen increased global demand for routine diagnostics, excluding COVID-19 testing sales. In the fourth quarter of 2024, rapid diagnostics, excluding COVID testing sales, increased by 16% year over year. Core Laboratory Diagnostics grew by 4%, driven by strong demand for Abbott’s immunoassay, clinical chemistry, hematology, and blood screening testing panels.

Abbott’s Diabetes Care business has benefited from the growing sales of its flagship, sensor-based continuous glucose monitoring system, FreeStyle Libre. FreeStyle Libre has achieved global leadership among continuous glucose monitoring (CGM) systems for both Type 1 and Type 2 users. In the fourth quarter, sales of CGM exceeded $1.8 billion and grew by 23%. In full-year 2024, sales of CGM were approximately $6.5 billion and grew by 22% from 2023, including a 27% growth in the United States.

Despite these positive developments, Abbott faces challenges due to foreign exchange fluctuations and a challenging macroeconomic environment. The strengthening of the euro and other developed market currencies has negatively impacted the company’s international performance. In the fourth quarter of 2024, foreign exchange had an unfavorable year-over-year impact of 1.4% on sales. Additionally, higher expenses for raw materials and freight, driven by a challenging macroeconomic scenario, could result in broader economic impacts and security concerns, affecting the company’s business in the upcoming months.